Literature DB >> 7531696

Recombinant GST/CD36 fusion proteins define a thrombospondin binding domain. Evidence for a single calcium-dependent binding site on CD36.

S Frieda1, A Pearce, J Wu, R L Silverstein.   

Abstract

CD36 is a multifunctional cell surface glycoprotein that acts as a surface receptor for thrombospondin (TSP), and thereby may mediate adhesive interactions between cells and substrata, platelets and other cells, and macrophages and apoptotic neutrophils. The identity of the TSP binding site on CD36 is controversial and may involve more than one structural domain. We have constructed a series of recombinant bacterial GST/CD36 fusion proteins that span nearly all of the CD36 molecule and have demonstrated that fusion proteins containing the region extending from amino acid 93 to 120 formed specific, saturable, and reversible complexes with TSP. As with intact CD36, binding was calcium-dependent, was independent of which ligand was immobilized, and was blocked by monoclonal antibodies to both CD36 and TSP. Stoichiometry and affinity of the fusion proteins for TSP were consistent with that of the intact protein. We also demonstrated that these fusion proteins competitively inhibited binding of TSP to purified platelet CD36 and to cell surface CD36 on peripheral blood monocytes and CD36 cDNA-transfected melanoma cells. These data demonstrate that the region between amino acids 93 and 120 has all of the characteristics required of the TSP binding domain.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7531696     DOI: 10.1074/jbc.270.7.2981

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

1.  Plasmodium yoelii sporozoites infect CD36-deficient mice.

Authors:  Photini Sinnis; Maria Febbraio
Journal:  Exp Parasitol       Date:  2002-01       Impact factor: 2.011

2.  A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation.

Authors:  Maria E Bamberger; Meera E Harris; Douglas R McDonald; Jens Husemann; Gary E Landreth
Journal:  J Neurosci       Date:  2003-04-01       Impact factor: 6.167

Review 3.  Thrombospondins in the transition from myocardial infarction to heart failure.

Authors:  Jonathan A Kirk; Oscar H Cingolani
Journal:  J Mol Cell Cardiol       Date:  2015-12-10       Impact factor: 5.000

4.  Molecular basis of human CD36 gene mutations.

Authors:  Monika Ewa Rać; Krzysztof Safranow; Wojciech Poncyljusz
Journal:  Mol Med       Date:  2007 May-Jun       Impact factor: 6.354

5.  OxLDL or TLR2-induced cytokine response is enhanced by oxLDL-independent novel domain on mouse CD36.

Authors:  Chenghui Xie; Hangpong Ng; Shanmugam Nagarajan
Journal:  Immunol Lett       Date:  2011-01-31       Impact factor: 3.685

Review 6.  CD36: implications in cardiovascular disease.

Authors:  Maria Febbraio; Roy L Silverstein
Journal:  Int J Biochem Cell Biol       Date:  2007-03-23       Impact factor: 5.085

7.  CD36 ectodomain phosphorylation blocks thrombospondin-1 binding: structure-function relationships and regulation by protein kinase C.

Authors:  Ling-Yun Chu; Roy L Silverstein
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-01-12       Impact factor: 8.311

Review 8.  Thrombospondin-1 and CD47 regulation of cardiac, pulmonary and vascular responses in health and disease.

Authors:  Natasha M Rogers; Maryam Sharifi-Sanjani; Gábor Csányi; Patrick J Pagano; Jeffrey S Isenberg
Journal:  Matrix Biol       Date:  2014-01-11       Impact factor: 11.583

9.  Critical residues and motifs for homodimerization of the first transmembrane domain of the plasma membrane glycoprotein CD36.

Authors:  Peng Wei; Fu-de Sun; Li-Min Zuo; Jing Qu; Peng Chen; Li-da Xu; Shi-Zhong Luo
Journal:  J Biol Chem       Date:  2017-03-23       Impact factor: 5.157

10.  Identification of the growth hormone-releasing peptide binding site in CD36: a photoaffinity cross-linking study.

Authors:  Annie Demers; Normand McNicoll; Maria Febbraio; Marc Servant; Sylvie Marleau; Roy Silverstein; Huy Ong
Journal:  Biochem J       Date:  2004-09-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.